Relay Therapeutics, Inc. 8-K

What Happened

• Relay Therapeutics, Inc. announced on March 6, 2026 that its Board approved an amendment and restatement of the company’s amended and restated bylaws, effective immediately, to designate the federal district courts of the United States as the exclusive forum for resolving complaints asserting causes of action under the Securities Act of 1933 or the Securities Exchange Act of 1934 (and related rules and regulations). The company filed the amendment on Form 8‑K dated March 11, 2026 and included the full bylaws as Exhibit 3.1.

Key Details

• Board approval date: March 6, 2026; amendment effective immediately upon approval.
• Scope: Applies to complaints asserting causes of action under the Securities Act of 1933, the Securities Exchange Act of 1934, and their respective rules and regulations.
• Filing: The amended and restated bylaws are attached as Exhibit 3.1 to the Form 8‑K filed March 11, 2026.
• Signature: Form 8‑K signed by Soo‑Yeun Lim, General Counsel.

Why It Matters

• The bylaw change specifies a single, federal venue for certain securities-related lawsuits against the company (unless Relay consents in writing to another forum). That centralizes where these types of claims must be brought, which can affect litigation procedure and forum selection for shareholders and plaintiffs. Investors should note the change as a governance update disclosed in the company’s Form 8‑K.